Samjin Pharmaceutical said Thursday it has officially launched “Newtoin Duo Tab,” a dual-action combination treatment designed to help manage symptoms of moderate to severe Alzheimer’s dementia.
Ahead of the launch, the company secured first generic exclusivity through a passive scope confirmation trial, laying strategic groundwork to gain an early foothold in the dementia combination-drug market.
Newtoin Duo Tab combines two active ingredients used in the company’s existing dementia treatment, Newtoin Tab: donepezil 10 milligrams, which inhibits the breakdown of acetylcholine to support signal transmission between brain nerve cells, and memantine 20 milligrams, commonly used for moderate to severe dementia to regulate excessive neural excitation and help prevent cognitive decline.
The two ingredients are known to work more effectively together in maintaining patients’ cognitive function and daily living abilities when administered in combination in clinical settings.
Consistent dosing at scheduled times is considered essential in dementia treatment, but elderly patients often face difficulties managing multiple medications separately. Samjin Pharm said the once-daily dosing format of Newtoin Duo Tab is expected to significantly improve medication adherence for both patients and caregivers.
As the domestic market for combination therapies targeting moderate to severe Alzheimer’s dementia continues to grow, the company said it plans to leverage its exclusivity rights and competitive pricing to help reduce the financial burden on patients and caregivers.
Samjin Pharm added that it will pursue tailored sales and marketing strategies focused on convenience and affordability to expand prescriptions and position the drug as a practical treatment option in clinical settings.
Kim Sang-jin, CEO of Samjin Pharm, said the company launched the product to address growing medical demand as the number of dementia patients rises alongside rapid population aging.
“We will continue striving to supply high-quality pharmaceuticals that contribute to public health based on differentiated formulation technologies,” Kim said.
The company also noted that pharmaceuticals should be used in consultation with medical professionals.
Separately, Samjin Pharm said it was recently selected for the Ministry of Trade, Industry and Energy’s “World Class Plus Project,” a government support program that provides mid-sized companies with research and development, export, financing and consulting support packages.
The initiative aims to foster globally competitive companies in advanced industries including biotech, semiconductors and artificial intelligence.
Samjin Pharm was selected as one of 10 promising mid-sized firms in the advanced biotech sector. Through the project, the company plans to accelerate global commercialization efforts centered on three growth engines: expanding indications for SJN314, establishing a full-cycle antibody-drug conjugate (ADC) platform, and advancing next-generation controlled-release formulation technologies.
